Côd QR

The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy

Human epidermal growth factor receptor 2 (HER2) is a clinically validated target for breast cancer therapy. Previously, a drug-fused HER2-targeting affinity protein construct successfully extended the survival of mice bearing HER2-expressing xenografts. The aim of this study was to evaluate the infl...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: Wen Yin, Tianqi Xu, Mohamed Altai, Maryam Oroujeni, Jie Zhang, Anzhelika Vorobyeva, Olga Vorontsova, Sergey V. Vtorushin, Vladimir Tolmachev, Torbjörn Gräslund, Anna Orlova
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: MDPI AG 2021-11-01
Cyfres:Pharmaceutics
Pynciau:
HER2
affibody molecule
albumin-binding domain
drug conjugate
targeted therapy
mertansine
Mynediad Ar-lein:https://www.mdpi.com/1999-4923/13/11/1974
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg